Pharmaceutical companies are exploring new strategies and alliance models to address the industry’s innovation gap. One approach is ”open innovation”—defined as “a paradigm that assumes that firms can and should use external ideas as well as internal ideas, and internal and external paths to market.” Increasingly, open innovation alliances among academia, government, non-profit organizations, and industry are seen as key to bringing new therapies to market. This panel will explore case studies of such alliances, ground-breaking partnerships that advance understanding of disease mechanisms and explore the utility of drug candidates beyond their current disease focus to identify new therapies.

Learning Objectives:

  • Share case studies of open innovation alliances that have been initiated this year
  • Examine open innovation as a possible working model for pharma
  • Discuss how collaborating across government, academia, and industry spurs innovation

Ability Level: All

Session ID: 1912

myBIO Chatter

Speakers (4)

contact_6265 Christopher P. Austin, MD Director, National Center for Advancing Translational Sciences National Institutes of Health
contact_9877 Ben Heywood Co-Founder and President PatientsLikeMe
contact_4689 Menelas Pangalos, PhD Executive Vice President, Innovative Medicines AstraZeneca
contact_8846 David Steinberg Partner Puretech Ventures

Moderators (1)

User Asher Mullard Senior News Editor Nature Reviews Drug Discovery